Trial NCT05429762

View at ClinicalTrials.gov 
Org. Study IDs: TES16382
Secondary IDs: 2022-001213-39 U1111-1269-6291

Last trial update was posted on 2024-04-12

MeSH Interventions

Maytansine

MeSH Conditions


Other Conditions

Neoplasm

Stopping Reasons

Tusamitamab ravtansine clinical development program is discontinued as CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival. The decision is not related to any safety concern.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID